We included studies concerning (1) the expression of E-cadherin in primary ovarian cancer tissue in relation to clinical parameters (FIGO, grade, histopathological type of tumor) and patient survival and (2) the expression of E-cadherin in primary ovarian cancer tissue and benign ovarian tumors. This evidence concerns the gene CDH1 and ovarian carcinoma.